These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12492205)

  • 1. Telomerase expression and p53 status in hepatocellular carcinoma.
    Kobayashi T; Sugawara Y; Shi YZ; Makuuchi M
    Am J Gastroenterol; 2002 Dec; 97(12):3166-71. PubMed ID: 12492205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
    Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
    Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.
    Nanashima A; Yano H; Yamaguchi H; Tanaka K; Shibasaki S; Sumida Y; Sawai T; Shindou H; Nakagoe T
    J Gastroenterol; 2004; 39(2):148-54. PubMed ID: 15069621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of human telomerase reverse transcriptase gene in HCC does not depend on proliferating cell nuclear antigen and P53].
    Zhang D; Li KZ; Dou KF; Gao ZQ; Song ZS; Zhao QC; Fu YC
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):721-2. PubMed ID: 15555445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
    Pan HW; Ou YH; Peng SY; Liu SH; Lai PL; Lee PH; Sheu JC; Chen CL; Hsu HC
    Cancer; 2003 Jul; 98(1):119-27. PubMed ID: 12833464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients.
    Tseng PL; Tai MH; Huang CC; Wang CC; Lin JW; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
    J Surg Oncol; 2008 Oct; 98(5):349-57. PubMed ID: 18646041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
    Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.
    Saini N; Srinivasan R; Chawla Y; Sharma S; Chakraborti A; Rajwanshi A
    Liver Int; 2009 Sep; 29(8):1162-70. PubMed ID: 19627485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of telomerase activity in hepatocellular carcinoma.
    Shimada M; Hasegawa H; Gion T; Utsunomiya T; Shirabe K; Takenaka K; Otsuka T; Maehara Y; Sugimachi K
    Am J Gastroenterol; 2000 Mar; 95(3):748-52. PubMed ID: 10710069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.
    Kao JT; Chuah SK; Huang CC; Chen CL; Wang CC; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
    Liver Int; 2007 Aug; 27(6):772-81. PubMed ID: 17617120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression and clinical significance of certain apoptosis and angiogenesis factors in hepatocellular carcinoma].
    Guo RP; Zhong C; Shi M; Zhang CQ; Wei W; Zhang YQ; Li JQ
    Zhonghua Wai Ke Za Zhi; 2006 Dec; 44(23):1626-30. PubMed ID: 17359695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
    Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
    J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and clinical significance of VEGF and MMP-9 in hepatocellular carcinoma].
    Zhong C; Guo RP; Shi M; Wei W; Yu WS; Li JQ
    Ai Zheng; 2006 May; 25(5):599-603. PubMed ID: 16687082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C.
    Sanefuji K; Kayashima H; Iguchi T; Sugimachi K; Yamashita Y; Yoshizumi T; Soejima Y; Nishizaki T; Taketomi A; Maehara Y
    J Surg Oncol; 2009 Jan; 99(1):32-7. PubMed ID: 18985618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical contribution to recurrence-free survival in patients with macrovascular-invasion-negative hepatocellular carcinoma.
    Tanaka S; Mogushi K; Yasen M; Noguchi N; Kudo A; Kurokawa T; Nakamura N; Inazawa J; Tanaka H; Arii S
    J Am Coll Surg; 2009 Mar; 208(3):368-74. PubMed ID: 19317998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma.
    Fang F; Luo LB; Tao YM; Wu F; Yang LY
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):409-16. PubMed ID: 19208663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation.
    Caruso ML; Valentini AM
    Anticancer Res; 1999; 19(5B):3853-6. PubMed ID: 10628323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients.
    Swellam M; Ismail M; Eissa S; Hamdy M; Mokhtar N
    IUBMB Life; 2004 Aug; 56(8):483-90. PubMed ID: 15545228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.
    Gao Q; Wang XY; Qiu SJ; Yamato I; Sho M; Nakajima Y; Zhou J; Li BZ; Shi YH; Xiao YS; Xu Y; Fan J
    Clin Cancer Res; 2009 Feb; 15(3):971-9. PubMed ID: 19188168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.